Key facts
- ARDX - ARDELYX, INC. has 29 insiders with reported activity on this page.
- Net insider value flow over the last year: -$466,070.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 29 Insiders of ARDELYX, INC.
- Symbol
- ARDX on Nasdaq
- Location
- Fremont, CA
Change
- Buy value: $3,409,471; sell value: $3,875,540.
- Net share flow: +96,101.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$466,070.
Buys
$3,409,471
Shares: 733,333
Insiders: 1
Sells
$3,875,541
Shares: 637,232
Insiders: 10
Net
-$466,070
Shares: +96,101
Insiders: -9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 252,975 | $0 | $1,568,459 | -$1,568,459 |
| 3-6 | 333,333 | 136,938 | $1,946,331 | $857,198 | +$1,089,133 |
| 6-9 | 0 | 161,768 | $0 | $942,421 | -$942,421 |
| 9-12 | 400,000 | 85,551 | $1,463,140 | $507,463 | +$955,677 |
ARDELYX, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David M. Mott | Director | $19,285,738 | +$3,409,471 | +21% | Filing P/S | 20 Feb 2026 |
| Forest Baskett | 10%+ Owner | $14,998,764 | Mixed | 09 Dec 2021 | ||
| Scott D. Sandell | 10%+ Owner | $14,998,764 | Mixed | 09 Dec 2021 | ||
| Michael Raab | President & CEO, Director | $11,799,363 | -$2,170,101 | -16% | Mixed | 21 May 2026 |
| Susan Rodriguez | Chief Commercial Officer | $3,844,258 | Mixed | 21 May 2024 | ||
| Eric D. Foster | Chief Commercial Officer | $3,095,283 | -$234,155 | -7% | Mixed | 21 May 2026 |
| Laura A. Williams | Chief Patient Officer | $3,055,204 | -$1,002,906 | -25% | Mixed | 21 May 2026 |
| Justin A. Renz | Chief Financial Officer | $2,902,017 | -$41,741 | -1.4% | Mixed | 21 Aug 2025 |
| Mike Kelliher | Chief Business Officer | $2,715,761 | -$164,443 | -5.7% | Mixed | 21 May 2026 |
| David P. Rosenbaum | Chief Development Officer | $2,521,763 | Mixed | 20 Nov 2024 | ||
| Elizabeth A. Grammer | Chief Legal and Administrative Officer | $2,136,132 | -$67,841 | -3.1% | Mixed | 21 Nov 2025 |
| John E. Bishop | Chief Technical and Quality Officer | $2,111,176 | -$33,039 | -1.5% | Filing P/S | 21 May 2026 |
| Robert Blanks | Chief Regulatory and Quality Affairs Officer | $1,843,891 | Mixed | 20 Nov 2024 | ||
| Edward R. Conner | Chief Medical Officer | $1,665,452 | Mixed | 01 Aug 2025 | ||
| Richard J. Rodgers | Director | $1,637,630 | Mixed | 18 Jun 2025 | ||
| James Parker Brady | Chief Human Resources Officer | $1,636,231 | -$26,438 | -1.6% | Filing P/S | 21 May 2026 |
| Susan Hohenleitner | Chief Financial Officer | $1,435,746 | -$21,005 | -1.4% | Filing P/S | 21 May 2026 |
| Felecia Ettenberg | Chief Legal Officer | $1,419,630 | Median | 20 Apr 2026 | ||
| William Charles Bertrand | Director | $1,244,563 | Mixed | 18 Jun 2025 | ||
| Rajani Dinavahi | Chief Medical Officer | $1,171,830 | Mixed | 01 Apr 2026 | ||
| Jan M. Lundberg | Director | $1,088,942 | Mixed | 15 Jun 2023 | ||
| Joseph J. Reilly | Senior Vice President and Chief Accounting Officer | $939,097 | -$113,872 | -11% | Filing P/S | 21 May 2026 |
| Jeffrey W. Jacobs | Chief Scientific Officer | $793,367 | Mixed | 22 Nov 2021 | ||
| Robert Ora Felsch | SVP Finance and Chief Accounting Officer | $722,169 | Mixed | 20 Aug 2024 | ||
| Onaiza Cadoret-Manier | Director | $694,099 | Mixed | 18 Jun 2025 | ||
| Muna Bhanji | Director | $637,281 | Mixed | 18 Jun 2025 | ||
| Robert B. Bazemore | Director | $257,905 | Mixed | 18 Jun 2025 | ||
| Merdad Parsey | Director | $226,872 | Mixed | 18 Jun 2025 | ||
| Geoffrey A. Block | Director | $114,230 | Mixed | 15 Jun 2023 |
Top shareholders of ARDELYX, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
Millennium Management LLC |
7.4%
|
18,043,970
|
$108,083,380 | +$29,483,912 | 31 Mar 2026 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
5.5%
|
13,604,307
|
$83,122,316 | +$12,289,611 | 31 Mar 2026 | |
| JANUS HENDERSON GROUP PLC |
13D/G
13F
|
Company |
3.4%
|
8,371,234
|
$51,148,240 | -$33,316,968 | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
|
Company |
3.2%
from 13D/G
|
17,842,370
|
$106,875,796 | — | 31 Mar 2026 | |
| Edward R. Conner |
3/4/5
|
Chief Medical Officer |
0.12%
|
302,260
|
$1,665,452 | — | 01 Aug 2025 | |
| Felecia Ettenberg |
3/4/5
|
Chief Legal Officer |
0.1%
|
237,000
|
$1,419,630 | — | 20 Apr 2026 | |
| Rajani Dinavahi |
3/4/5
|
Chief Medical Officer |
0.08%
|
201,000
|
$1,171,830 | — | 01 Apr 2026 | |
| BlackRock, Inc. |
13F
|
Company |
8.6%
|
21,164,132
|
$126,773,151 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.2%
|
10,365,512
|
$62,089,417 | — | 31 Mar 2026 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. |
13F
|
Company |
3.3%
|
8,169,369
|
$48,935,000 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
2.7%
|
6,661,693
|
$39,903,541 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
6,007,455
|
$35,991,723 | — | 31 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
2.1%
|
5,234,683
|
$31,355,751 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.7%
|
4,274,043
|
$25,601,518 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.4%
|
3,464,774
|
$20,753,997 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
3,216,210
|
$19,265,098 | — | 31 Mar 2026 | |
| J. Goldman & Co LP |
13F
|
Company |
1.2%
|
3,000,513
|
$17,973,073 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.2%
|
2,984,261
|
$17,875,723 | — | 31 Mar 2026 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.99%
|
2,439,450
|
$14,612,307 | — | 31 Mar 2026 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.99%
|
2,435,548
|
$14,588,933 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.95%
|
2,336,994
|
$13,998,594 | — | 31 Mar 2026 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.93%
|
2,299,473
|
$13,773,843 | — | 31 Mar 2026 | |
| Eversept Partners, LP |
13F
|
Company |
0.91%
|
2,229,446
|
$13,354,382 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.86%
|
2,114,098
|
$12,663,447 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.84%
|
2,071,047
|
$12,405,571 | — | 31 Mar 2026 | |
| Freestone Grove Partners LP |
13F
|
Company |
0.76%
|
1,879,783
|
$11,259,900 | — | 31 Mar 2026 | |
| Rubric Capital Management LP |
13F
|
Company |
0.76%
|
1,860,896
|
$11,146,767 | — | 31 Mar 2026 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0.75%
|
1,858,891
|
$10,186,723 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.69%
|
1,708,973
|
$10,236,755 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.68%
|
1,678,111
|
$10,051,885 | — | 31 Mar 2026 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.65%
|
1,600,857
|
$9,589,136 | — | 31 Mar 2026 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.61%
|
1,498,798
|
$8,977,800 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.52%
|
1,272,441
|
$7,621,922 | — | 31 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.48%
|
1,179,379
|
$7,064,480 | — | 31 Mar 2026 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.41%
|
1,001,481
|
$5,998,871 | — | 31 Mar 2026 | |
| Trexquant Investment LP |
13F
|
Company |
0.33%
|
804,734
|
$4,820,357 | — | 31 Mar 2026 | |
| Redmile Group, LLC |
13F
|
Company |
0.3%
|
733,350
|
$4,392,767 | — | 31 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.29%
|
708,589
|
$4,244,448 | — | 31 Mar 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.29%
|
701,968
|
$4,204,788 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.28%
|
700,783
|
$4,197,692 | — | 31 Mar 2026 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.28%
|
698,744
|
$4,185,477 | — | 31 Mar 2026 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.28%
|
697,284
|
$4,176,731 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.28%
|
688,649
|
$4,125,007 | — | 31 Mar 2026 | |
| Gamma As Sector |
13F
|
Individual |
0.21%
|
516,131
|
$3,091,625 | — | 31 Mar 2026 | |
| Krensavage Asset Management, LLC |
13F
|
Company |
0.2%
|
500,000
|
$2,995,000 | — | 31 Mar 2026 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.2%
|
486,712
|
$2,915,405 | — | 31 Mar 2026 | |
| Swiss National Bank |
13F
|
Company |
0.2%
|
480,800
|
$2,879,992 | — | 31 Mar 2026 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.19%
|
473,061
|
$2,834,000 | — | 31 Mar 2026 | |
| Ishara Investments LP |
13F
|
Company |
0.18%
|
451,000
|
$2,701,490 | — | 31 Mar 2026 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.18%
|
450,738
|
$2,699,921 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for ARDELYX, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Joseph J. Reilly | ARDX | Common Stock | Sale | -2.43% | $23,309 | $6.27 | -3,719 | 149,107 | 21 May 2026 | Direct |
| Susan Hohenleitner | ARDX | Common Stock | Sale | -0.63% | $9,119 | $6.27 | -1,455 | 229,078 | 21 May 2026 | Direct |
| John E. Bishop | ARDX | Common Stock | Sale | -0.68% | $14,453 | $6.27 | -2,306 | 336,845 | 21 May 2026 | Direct |
| James Parker Brady | ARDX | Common Stock | Sale | -0.7% | $11,570 | $6.27 | -1,846 | 261,066 | 21 May 2026 | Direct |
| Eric D. Foster | ARDX | Common Stock | Sale | -1.88% | $50,127 | $6.27 | -7,998 | 417,972 | 21 May 2026 | Direct |
| Mike Kelliher | ARDX | Common Stock | Sale | -1.99% | $45,427 | $6.27 | -7,248 | 357,418 | 21 May 2026 | Direct |
| Laura A. Williams | ARDX | Common Stock | Sale | -1.6% | $43,804 | $6.27 | -6,989 | 429,093 | 21 May 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Sale | -3.08% | $343,133 | $6.27 | -54,748 | 1,720,033 | 21 May 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Sale | -2.29% | $261,612 | $6.28 | -41,666 | 1,774,781 | 15 May 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Options Exercise | 1.16% | 20,833 | 1,816,447 | 15 May 2026 | Direct | ||
| Michael Raab | ARDX | Stock Option (Right to Buy) | Options Exercise | -5.9% | -20,833 | 332,501 | 15 May 2026 | Direct | ||
| Michael Raab | ARDX | Common Stock | Sale | -2.27% | $261,954 | $6.29 | -41,668 | 1,795,614 | 15 Apr 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Options Exercise | 1.15% | 20,834 | 1,837,282 | 15 Apr 2026 | Direct | ||
| Michael Raab | ARDX | Stock Option (Right to Buy) | Options Exercise | -5.57% | -20,834 | 353,334 | 15 Apr 2026 | Direct | ||
| Michael Raab | ARDX | Common Stock | Sale | -2.24% | $243,329 | $5.84 | -41,666 | 1,816,448 | 16 Mar 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Options Exercise | 1.13% | 20,833 | 1,856,986 | 16 Mar 2026 | Direct | ||
| Michael Raab | ARDX | Stock Option (Right to Buy) | Options Exercise | -5.27% | -20,833 | 374,168 | 16 Mar 2026 | Direct | ||
| Michael Raab | ARDX | Common Stock | Sale | -2.22% | $260,621 | $6.26 | -41,666 | 1,836,153 | 24 Feb 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Options Exercise | 1.12% | 20,833 | 1,877,819 | 24 Feb 2026 | Direct | ||
| Michael Raab | ARDX | Stock Option (Right to Buy) | Options Exercise | -5.01% | -20,833 | 395,001 | 24 Feb 2026 | Direct | ||
| David M. Mott | ARDX | Common Stock | Purchase | 11.2% | $1,946,331 | $5.84 | 333,333 | 3,302,918 | 20 Feb 2026 | Direct |
| John E. Bishop | ARDX | Common Stock | Sale | -0.93% | $18,586 | $5.85 | -3,179 | 339,151 | 20 Feb 2026 | Direct |
| Joseph J. Reilly | ARDX | Common Stock | Sale | -3.18% | $29,181 | $5.85 | -4,991 | 151,790 | 20 Feb 2026 | Direct |
| Laura A. Williams | ARDX | Common Stock | Sale | -1.84% | $47,803 | $5.85 | -8,176 | 436,082 | 20 Feb 2026 | Direct |
| Susan Hohenleitner | ARDX | Common Stock | Sale | -0.87% | $11,886 | $5.85 | -2,033 | 230,533 | 20 Feb 2026 | Direct |
| James Parker Brady | ARDX | Common Stock | Sale | -0.96% | $14,868 | $5.85 | -2,543 | 262,912 | 20 Feb 2026 | Direct |
| Mike Kelliher | ARDX | Common Stock | Sale | -2.56% | $56,099 | $5.85 | -9,595 | 364,666 | 20 Feb 2026 | Direct |
| Michael Raab | ARDX | Common Stock | Sale | -2.42% | $268,841 | $5.85 | -45,982 | 1,856,986 | 20 Feb 2026 | Direct |
| Eric D. Foster | ARDX | Common Stock | Sale | -2.39% | $61,034 | $5.85 | -10,439 | 425,970 | 20 Feb 2026 | Direct |
| Joseph J. Reilly | ARDX | Common Stock | Award | 41.8% | 46,200 | 156,781 | 23 Jan 2026 | Direct | ||
| Joseph J. Reilly | ARDX | Stock Option (Right to Buy) | Award | 69,360 | 69,360 | 23 Jan 2026 | Direct | |||
| Mike Kelliher | ARDX | Common Stock | Award | 38% | 103,080 | 374,261 | 23 Jan 2026 | Direct | ||
| Mike Kelliher | ARDX | Stock Option (Right to Buy) | Award | 154,625 | 154,625 | 23 Jan 2026 | Direct | |||
| Susan Hohenleitner | ARDX | Common Stock | Award | 58.3% | 85,670 | 232,566 | 23 Jan 2026 | Direct | ||
| Susan Hohenleitner | ARDX | Stock Option (Right to Buy) | Award | 128,505 | 128,505 | 23 Jan 2026 | Direct | |||
| Eric D. Foster | ARDX | Common Stock | Award | 46.2% | 137,945 | 436,409 | 23 Jan 2026 | Direct | ||
| Eric D. Foster | ARDX | Stock Option (Right to Buy) | Award | 206,915 | 206,915 | 23 Jan 2026 | Direct | |||
| James Parker Brady | ARDX | Common Stock | Award | 59.9% | 99,455 | 265,455 | 23 Jan 2026 | Direct | ||
| James Parker Brady | ARDX | Stock Option (Right to Buy) | Award | 149,185 | 149,185 | 23 Jan 2026 | Direct | |||
| Laura A. Williams | ARDX | Common Stock | Award | 22.9% | 82,695 | 444,258 | 23 Jan 2026 | Direct | ||
| Laura A. Williams | ARDX | Stock Option (Right to Buy) | Award | 124,040 | 124,040 | 23 Jan 2026 | Direct | |||
| Michael Raab | ARDX | Common Stock | Award | 30.6% | 446,220 | 1,902,968 | 23 Jan 2026 | Direct | ||
| Michael Raab | ARDX | Stock Option (Right to Buy) | Award | 669,330 | 669,330 | 23 Jan 2026 | Direct | |||
| John E. Bishop | ARDX | Common Stock | Award | 57% | 124,330 | 342,330 | 23 Jan 2026 | Direct | ||
| John E. Bishop | ARDX | Stock Option (Right to Buy) | Award | 186,500 | 186,500 | 23 Jan 2026 | Direct | |||
| Laura A. Williams | ARDX | Common Stock | Sale | -12.2% | $348,900 | $6.98 | -50,000 | 361,563 | 08 Jan 2026 | Direct |
| Laura A. Williams | ARDX | Common Stock | Options Exercise | 13.9% | 50,000 | 409,896 | 08 Jan 2026 | Direct | ||
| Laura A. Williams | ARDX | Stock Option (Right to Buy) | Options Exercise | 0 | 62,000 | 08 Jan 2026 | Direct | |||
| Elizabeth A. Grammer | ARDX | Common Stock | Sale | -1.96% | $33,194 | $5.54 | -5,995 | 299,895 | 21 Nov 2025 | Direct |
| Michael Raab | ARDX | Common Stock | Sale | -3.12% | $259,609 | $5.54 | -46,887 | 1,455,363 | 21 Nov 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.